Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jan 15:8:20.
doi: 10.1186/1743-422X-8-20.

An overview of treatment response rates to various anti-viral drugs in Pakistani hepatitis B virus infected patients

Liaqat Ali  1 , Muhammad Idrees, Muhammad Ali, Irshad-ur Rehman, Abrar Hussain, Samia Afzal, Sadia Butt, Sana Saleem, Saira Munir, Sadaf Badar
Affiliations
Review

An overview of treatment response rates to various anti-viral drugs in Pakistani hepatitis B virus infected patients

Liaqat Ali et al. Virol J. .

Abstract

Hepatitis B virus (HBV) is one of the leading health problem with up to 350 million affected people worldwide including 4.5 million only in Pakistan. It has mortality rate of 0.5 to 1.2 million per year worldwide. Pakistan lies in the endemic region with 3-5% HBV carrier rate in the country. The present article reviews the literature on the treatment response of HBV prevalent in Pakistani population. The average treatment response of Lamivudine and interferon-α is 25.81% and 47.95%, respectively. Peg-Interferon was shown to be not effective against the HBV/HCV (hepatitis C virus)/HDV (hepatitis Delta virus) co-infection. The present study reveals that interferon-α is the most effective therapy available for HBV infection prevalent in Pakistani population. Genotype C & D are the most common HBV genotypes in Pakistan and are associated with increased severity and less response to interferon therapy. This poses a great challenge for physicians and researchers and further studies are needed to describe the outcome of the current therapies recommended against HBV infection in Pakistani population.

PubMed Disclaimer

References

    1. Awan Z, Idrees M, Rafique S, Rehman I, Akbar H, But S. et al. Hepatitis B virus YMDD-motif mutations with emergence of lamivudine-resistant mutants: a threat to recovery. Gastroenterology and Hepatology From Bed to Bench. 2010;3:108–114.
    1. Lee W. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745. doi: 10.1056/NEJM199712113372406. - DOI - PubMed
    1. Ganem D, Schneiden RJ, In: Fields Virology. Knipe DM, Howely PM, Griffin DE, editor. Philadelphia: Lippincott-Raven; 2001. Hepadnaviridae: the viruses and their replication; pp. 292–2969.
    1. Klingmuller U, Schallen H. Hepadnavirus infection requires interaction between the viral pre-s domain and a specific hepatocellular receptor. J Virol. 1993;67:7414–7422. - PMC - PubMed
    1. Sugauchi F, Chutaputti A, Orito E, Kato H, Suzuki S, Ueda R, Mizokami M. Hepatitis B virus genotypes and clinical manifestation among hepatitis B carriers in Thailand. J Gastroenterol Hepatol. 2002;17:671–676. doi: 10.1046/j.1440-1746.2002.02754.x. - DOI - PubMed